Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Website URL
Similar Companies999
ILIAS Biologics
ILIAS Biologics develops exosome-based therapeutics for hard-to-treat inflammatory and metabolic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company that develops innovative targeted biologic drugs using its proprietary FHAB™ technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
Coherus Biosciences
Coherus Biosciences develops and sells biologic therapeutics for oncology and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Avidity Biosciences
Avidity Biosciences is a biotech company developing oligonucleotide-based therapies to treat serious diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds5
Number of Funding Rounds
Money Raised
Their latest funding was raised on 29.08.2023. Their latest investor Perceptive Advisors. Their latest round Post-IPO Equity
RA Capital Management
RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Viking Global Investors
Viking Global Investors manages over $40 billion of capital across long/short, long-only, public/private hybrid and private-only strategies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors10
Number of lead investors
Number of investors
Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
RA Capital Management
RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Viking Global Investors
Viking Global Investors manages over $40 billion of capital across long/short, long-only, public/private hybrid and private-only strategies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders3
Brendan Eckelman
Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporation strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine
current job
Brendan Eckelman
Quinn Deveraux
Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrx’s biotherapeutic pipeline. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn lead groups of Ph.D./M.D. level investigators in the conception and development of novel target identification and validation platforms. Quinn lead the first therapeutic antibody from GNF to transition from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute was highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.
current job
organization founded
Quinn Deveraux
Mark Lappe
Mark has extensive expertise in the biotechnology industry with over twenty years of experience in investment management and building the executive teams of over forty start-up biotechnology and medical device companies. Prior to starting Inhibrx, Mark was the Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in emerging public biotechnology companies. Mark has significant experience in the antibody field through Efficacy’s major investment in Arius Research. Efficacy played the key advisor to Arius and developed the exit strategy that led to the successful sale to Roche in 2008. Additionally, Mark served as a board member of two public biotech companies.
current job
organization founded
Mark Lappe
Employee Profiles8
Activity
Recent News16
The graph reveals the ratio (%) of positive news articles in a chosen time range